Combined effects of host antitumor immune responses and chemotherapy. Studies with hexamethylmelamine.
The antitumor activity of hexamethylmelamine (HMM) was tested in various mouse tumor models in the presence or absence of host-vs-tumor graft responses. The drug was moderately active against Sarcoma-180 growing in different strains of non-sensitized mice. Strong protection was afforded when recipients were preimmunized with irradiated tumor cells 15 days before tumor challenge followed by HMM treatment. The drug did not show antitumor activity against two radiation-induced lymphomas of congenic mice of B10 background, inoculated into H-2 compatible hosts, or into mice incompatible for subregions of H-2. In this model HMM increased mortality of allogeneic mice presumably through impairment of host-vs-lymphoma graft resistance. In conclusion this study shows that synergistic or antagonistic effects can be obtained by combining chemotherapy with antitumor immune responses.
D006585:Altretamine / Q000627:therapeutic use*; D000818:Animals; D006789:Host vs Graft Reaction / Q000187:drug effects*; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology*; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy / Q000276:immunology; D012510:Sarcoma 180 / Q000188:drug therapy / Q000276:immunology; D014227:Triazines / Q000627:therapeutic use*
D014227:Triazines; D006585:Altretamine